Tandem Control-IQ Evaluation Regarding Glucose Metrics, Sleep, and Health Economics
NCT ID: NCT05969106
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
84 participants
OBSERVATIONAL
2020-01-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing the Impact of Control-IQ Technology
NCT04838561
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
NCT05683392
CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
NCT02092051
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
NCT05422053
Hybrid Closed Loop in High Risk Youth With Type 1 Diabetes
NCT04807374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rtCGM + MDI
Real-time CGM Dexcom G6 used in parallel to Multiple Daily Injections (MDI)
Tandem Control-IQ
AID-system
rtCGM + CSII
Real-time CGM Dexcom G6 used in parallel to freestanding Continuous Subcutaneous Insulin Infusion (CSII)
Tandem Control-IQ
AID-system
Tandem Control-IQ
Realtime CGM Dexcom G6 used as part of the Automated Insulin Delivery (AID) system
Tandem Control-IQ
AID-system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tandem Control-IQ
AID-system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with Type 1 diabetes
* Min duration three months
* Willingness to participate in the study
Exclusion Criteria
* Unwillingness to share and upload CGM data
* Reluctance to come to visit and to follow protocol
* History of allergic reaction to Dexcom CGM materials or adhesives in contact with the skin.
* Abnormal skin at the anticipated glucose sensor attachment sites(excessive hair, burn, inflammation, infection, rash, and/or tattoo)
2 Years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vastra Gotaland Region
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Johan Peter Adolfsson
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Adolfsson, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Västra Götalandsregionen, Gothenburg University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The hospital of Halland Kungsbacka
Kungsbacka, Region of Halland, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VastraGotaland - 2022-00332-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.